Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at Jefferies Financial Group cut their Q1 2019 earnings estimates for Hologic in a report issued on Wednesday, November 7th. Jefferies Financial Group analyst R. Denhoy now expects that the medical equipment provider will post earnings of $0.56 per share for the quarter, down from their previous forecast of $0.58. Jefferies Financial Group currently has a “Buy” rating and a $50.00 price target on the stock. Jefferies Financial Group also issued estimates for Hologic’s Q4 2019 earnings at $0.63 EPS, FY2019 earnings at $2.39 EPS, FY2020 earnings at $2.59 EPS and FY2022 earnings at $3.07 EPS.

A number of other research analysts also recently commented on HOLX. BidaskClub upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Wednesday, August 1st. Needham & Company LLC upped their price target on Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Deutsche Bank upped their price target on Hologic from $42.00 to $45.00 and gave the stock a “hold” rating in a research note on Wednesday, August 1st. Bank of America upped their price target on Hologic from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Finally, Cowen reiterated a “buy” rating and set a $45.00 price target on shares of Hologic in a research note on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $44.41.

Shares of NASDAQ HOLX opened at $41.78 on Friday. The company has a current ratio of 1.29, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Hologic has a one year low of $35.10 and a one year high of $45.09. The stock has a market capitalization of $11.23 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 1.88 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.01). Hologic had a negative net margin of 3.46% and a positive return on equity of 22.93%. The firm had revenue of $813.50 million during the quarter, compared to analysts’ expectations of $808.63 million. During the same quarter last year, the firm earned $0.50 EPS. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year.

In related news, Director Sally Crawford sold 13,257 shares of the business’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $39.54, for a total transaction of $524,181.78. Following the completion of the transaction, the director now owns 167,701 shares of the company’s stock, valued at approximately $6,630,897.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin Jordan Cohn sold 3,437 shares of the business’s stock in a transaction dated Wednesday, September 19th. The stock was sold at an average price of $41.50, for a total value of $142,635.50. Following the transaction, the insider now directly owns 16,520 shares of the company’s stock, valued at approximately $685,580. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,519 shares of company stock valued at $2,003,965. 0.79% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC World Markets Inc. lifted its position in shares of Hologic by 217.5% during the 3rd quarter. CIBC World Markets Inc. now owns 26,978 shares of the medical equipment provider’s stock worth $1,106,000 after purchasing an additional 18,481 shares during the last quarter. FMR LLC lifted its position in shares of Hologic by 6.4% during the 3rd quarter. FMR LLC now owns 2,438,184 shares of the medical equipment provider’s stock worth $99,916,000 after purchasing an additional 146,726 shares during the last quarter. Rafferty Asset Management LLC lifted its position in shares of Hologic by 14.4% during the 3rd quarter. Rafferty Asset Management LLC now owns 48,207 shares of the medical equipment provider’s stock worth $1,976,000 after purchasing an additional 6,059 shares during the last quarter. American International Group Inc. lifted its position in shares of Hologic by 4.9% during the 3rd quarter. American International Group Inc. now owns 110,131 shares of the medical equipment provider’s stock worth $4,513,000 after purchasing an additional 5,170 shares during the last quarter. Finally, BlackRock Inc. lifted its position in shares of Hologic by 0.9% during the 3rd quarter. BlackRock Inc. now owns 18,773,720 shares of the medical equipment provider’s stock worth $769,349,000 after purchasing an additional 164,937 shares during the last quarter. 98.74% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Inflation

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.